CDT Equity Inc. entered into amendments to its senior secured convertible promissory note with J.J. Astor & Co., increasing the principal balance from $1,971,000 to $2,536,650 through a second amendment on July 31, 2026, and a third advance of $200,000 on August 3, 2026. The amended note carries a 19% interest rate and requires repayment over twenty-three weekly installments of $104,187.65 starting August 19, 2026. To service this debt, the company increased the net proceeds share from its sales agreement with A.G.P./Alliance Global Partners to ninety percent. The lender received warrants for 37,500 shares at $7.20 per share and retains conversion rights into common stock at a price based on seventy percent of the lowest VWAP over twenty trading days. The company must file a resale registration statement by August 31, 2026, with effectiveness by September 11, 2026, and obtain shareholder approval for equity issuances by August 28, 2026. CDT Equity Inc. operates in the financial services industry, focusing on investment management and capital markets activities.

CDT Equity Inc. announced a 1-for-10 reverse stock split to ensure continued compliance with the Nasdaq bid-price rule. The split becomes effective on July 17, 2026, and the company's common stock is expected to begin trading on a reverse stock split-adjusted basis on July 20, 2026. CDT Equity Inc. is a data-driven biopharmaceutical development company focused on therapeutic asset advancement through scientific innovation and strategic partnerships.

CDT Equity Inc. entered into an Amended and Restated Loan Agreement and an Amended and Restated Senior Secured Convertible Promissory Note with J.J. Astor & Co. to close the second tranche of a $1,971,000 loan. The company will begin making twenty-four equal weekly installment payments of $82,125 starting July 10, 2026. CDT Equity Inc. is a financial services company.